These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34952583)

  • 41. Modeling the Etiology of p53-mutated Cancer Cells.
    Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
    J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
    Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
    Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutant p53: it's not all one and the same.
    Kennedy MC; Lowe SW
    Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of mutant p53 stabilization in cancer.
    Frum RA; Grossman SR
    Subcell Biochem; 2014; 85():187-97. PubMed ID: 25201195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Contrived Mutant p53 Oncogene - Beyond Loss of Functions.
    Sabapathy K
    Front Oncol; 2015; 5():276. PubMed ID: 26697411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
    Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
    Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment.
    Bhatta B; Luz I; Krueger C; Teo FX; Lane DP; Sabapathy K; Cooks T
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.
    Ho T; Tan BX; Lane D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the DNA Damage Response in OSCC with TP53 Mutations.
    Lindemann A; Takahashi H; Patel AA; Osman AA; Myers JN
    J Dent Res; 2018 Jun; 97(6):635-644. PubMed ID: 29489434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.
    Chasov V; Zaripov M; Mirgayazova R; Khadiullina R; Zmievskaya E; Ganeeva I; Valiullina A; Rizvanov A; Bulatov E
    Front Immunol; 2021; 12():707734. PubMed ID: 34484205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
    Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
    Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
    Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
    [No Abstract]   [Full Text] [Related]  

  • 56. Antitumor Effects of PRIMA-1 and PRIMA-1
    Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.
    Lu X; Liu DP; Xu Y
    Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
    Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
    Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
    Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
    Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological activation of p53 in cancer cells.
    Athar M; Elmets CA; Kopelovich L
    Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.